New answers on PD-L1
February 2017

HOUSTON—Recent work from scientists at MD Anderson Cancer Center, led by Dr. Mien-Chie Hung, chair of Molecular and Cellular Oncology, has uncovered new insight into how PD-L1 suppresses the immune system. The team found a previously unknown immunosuppression mechanism in cancer cells: inhibition of protein CSN5 activity blocked PD-L1’s ability to avoid the immune system. Specifically, CSN5 affects PD-L1’s interaction with PD-1, a cell receptor that blocks T cell activation when it binds with PD-L1. TNFa was also found to impact CSN5’s ability to ‘stabilize’ PD-L1 and boost its interaction with PD-1.
“This regulatory event is critical for breast cancer cells to escape immune surveillance via interaction between PD-L1 and PD-1,” Hung explained. “Importantly, inhibition of TNFa-mediated PD-L1 stabilization in cancer cells promotes the tumor-infiltrating immune response. Thus, targeting cancer cell PD-L1 stabilization through CSN5 inhibition could help us develop better treatments for cancer accompanied by inflammation.”

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.